[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017015036A - Conjugados fluorescentes. - Google Patents

Conjugados fluorescentes.

Info

Publication number
MX2017015036A
MX2017015036A MX2017015036A MX2017015036A MX2017015036A MX 2017015036 A MX2017015036 A MX 2017015036A MX 2017015036 A MX2017015036 A MX 2017015036A MX 2017015036 A MX2017015036 A MX 2017015036A MX 2017015036 A MX2017015036 A MX 2017015036A
Authority
MX
Mexico
Prior art keywords
moiety
tumour
conjugate
fluorescent conjugates
targeting moiety
Prior art date
Application number
MX2017015036A
Other languages
English (en)
Inventor
Cailler Françoise
Framery Bérénice
Original Assignee
Surgimab S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surgimab S A S filed Critical Surgimab S A S
Publication of MX2017015036A publication Critical patent/MX2017015036A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058Antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/006Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007Carcino-embryonic Antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)

Abstract

La invención proporciona un conjugado con una fracción de fluorocromo F acoplada a una fracción objetivo T. La fracción F se describe mediante la Fórmula (I), y la fracción objetivo T se caracteriza por tener afinidad con un marcador tumoral, tal como un anticuerpo o fragmento de anticuerpo. El conjugado puede utilizarse para diagnóstico de tumores, incluyendo la fotodetección de nódulos tumorales durante la cirugía de resección.
MX2017015036A 2015-06-03 2016-06-02 Conjugados fluorescentes. MX2017015036A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15170617 2015-06-03
PCT/EP2016/062557 WO2016193396A1 (en) 2015-06-03 2016-06-02 Fluorescent conjugates

Publications (1)

Publication Number Publication Date
MX2017015036A true MX2017015036A (es) 2018-06-07

Family

ID=53365860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015036A MX2017015036A (es) 2015-06-03 2016-06-02 Conjugados fluorescentes.

Country Status (22)

Country Link
US (2) US9821079B2 (es)
EP (1) EP3166606B1 (es)
JP (1) JP6912389B2 (es)
KR (1) KR102681997B1 (es)
CN (1) CN107949385B (es)
AR (1) AR104895A1 (es)
AU (1) AU2016271853B2 (es)
CA (1) CA2986078C (es)
CL (1) CL2017003000A1 (es)
DK (1) DK3166606T3 (es)
ES (1) ES2683554T3 (es)
HR (1) HRP20181164T1 (es)
HU (1) HUE038696T2 (es)
IL (1) IL255633B (es)
MX (1) MX2017015036A (es)
PL (1) PL3166606T3 (es)
PT (1) PT3166606T (es)
RU (1) RU2720976C2 (es)
TR (1) TR201810532T4 (es)
TW (1) TWI702259B (es)
WO (1) WO2016193396A1 (es)
ZA (1) ZA201707817B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6912389B2 (ja) * 2015-06-03 2021-08-04 サージマブ エス.アー.エス. 蛍光コンジュゲート
EP3712617B1 (en) * 2019-03-19 2022-01-26 Miltenyi Biotec B.V. & Co. KG Method for providing personalized cells with chimeric antigen receptors (car)
CN112851809A (zh) * 2021-01-20 2021-05-28 上海交通大学 一种抗终末糖基化蛋白受体的抗体及其应用
WO2023114248A1 (en) * 2021-12-16 2023-06-22 Curadel Surgical Innovations, Inc. Near-infrared fluorescent contrast bioimaging agents for imaging of sentinel lymph nodes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
EA200200635A1 (ru) * 1999-12-15 2002-12-26 Шеринг Акциенгезельшафт Флуоресцентный контрастный агент для ближней инфракрасной области спектра и способ флуоресцентной визуализации
WO2006036071A2 (en) * 2004-09-29 2006-04-06 Ge Healthcare As Urokinase plasminogen activator receptor targeted contrast agent
FR2889700B1 (fr) 2005-08-11 2012-11-23 Synthinnove Lab Marqueurs, leur procede de fabrication et leurs applications
EP2257309B1 (en) * 2008-02-27 2019-10-16 Yeda Research And Development Company Ltd. Rgd-(bacterio)chlorophyll conjugates for use in diagnosis of tumors comprising necrotic domains
US9051263B2 (en) 2010-08-25 2015-06-09 Pacific Biosciences Of California, Inc. Functionalized cyanine dyes (PEG)
WO2012054784A1 (en) * 2010-10-20 2012-04-26 Li-Cor, Inc. Fluorescent imaging with substituted cyanine dyes
US9751868B2 (en) * 2012-02-28 2017-09-05 Pierce Biotechnology, Inc. Benzocyanine compounds
JP6912389B2 (ja) * 2015-06-03 2021-08-04 サージマブ エス.アー.エス. 蛍光コンジュゲート

Also Published As

Publication number Publication date
JP2018525329A (ja) 2018-09-06
PT3166606T (pt) 2018-10-01
EP3166606A1 (en) 2017-05-17
AU2016271853B2 (en) 2020-10-22
PL3166606T3 (pl) 2018-10-31
AU2016271853A1 (en) 2017-12-07
US20180126009A1 (en) 2018-05-10
US10159757B2 (en) 2018-12-25
EP3166606B1 (en) 2018-05-09
CA2986078A1 (en) 2016-12-08
CN107949385B (zh) 2021-04-09
CL2017003000A1 (es) 2018-05-18
AR104895A1 (es) 2017-08-23
TR201810532T4 (tr) 2018-08-27
RU2720976C2 (ru) 2020-05-15
NZ737353A (en) 2023-12-22
WO2016193396A1 (en) 2016-12-08
IL255633A (en) 2018-01-31
KR102681997B1 (ko) 2024-07-04
CA2986078C (en) 2023-09-12
ZA201707817B (en) 2019-11-27
IL255633B (en) 2020-09-30
JP6912389B2 (ja) 2021-08-04
DK3166606T3 (en) 2018-08-13
HRP20181164T1 (hr) 2018-09-21
RU2017141422A3 (es) 2019-10-28
TW201708407A (zh) 2017-03-01
BR112017025935A2 (pt) 2018-08-14
US9821079B2 (en) 2017-11-21
TWI702259B (zh) 2020-08-21
CN107949385A (zh) 2018-04-20
KR20180014027A (ko) 2018-02-07
ES2683554T3 (es) 2018-09-26
US20170035915A1 (en) 2017-02-09
RU2017141422A (ru) 2019-07-09
HUE038696T2 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
CY1118761T1 (el) Αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης 3 (her3)
MX2020002183A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos.
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MA40074A (fr) Composés liant ras multivalents
TN2015000396A1 (en) Antibody drug conjugates
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
UA117364C2 (uk) Похідні аматоксину
EA201790173A1 (ru) Антитела, связывающие axl
EA201291194A1 (ru) Индолы
EA201992595A1 (ru) Усиление фармакокинетики бифункциональных хелатов и их применения
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
TN2016000472A1 (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer.
EA201691952A1 (ru) Композиции и методы, имеющие отношение к диагностике рака предстательной железы
PH12017501879A1 (en) Methods for treating cancer
MX2017015036A (es) Conjugados fluorescentes.
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка

Legal Events

Date Code Title Description
FG Grant or registration